MarketScreener Strategies Genmab A/S Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 34.41 USD | +0.57% |
|
+0.91% | +11.72% |
| 09-03 | Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo | FW |
| 09-01 | Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy | FW |
MarketScreener Strategies
Search
 | Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course | August 07, 2026 at 02:12 pm |
 | Genmab soars after raising its guidance | August 07, 2026 at 09:00 am |
 | Genmab rebounds on a European Commission decision | July 07, 2026 at 08:52 am |
 | Genmab: Financing weighs now, pipeline pays later | June 23, 2026 at 12:20 pm |
| Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis | May 09, 2026 at 01:05 pm |
| Genmab: 2025 miss and cautious 2026 targets erode investor confidence | February 18, 2026 at 02:09 pm |
| Genmab advances on earnings strength and pipeline while lower valuation opens upside | November 07, 2025 at 03:01 pm |
| Genmab: A bold shift from defensive to aggressive | September 29, 2025 at 03:45 pm |
 | Genmab: From now on, courage to the most patient | April 01, 2025 at 03:57 pm |
No results match your criteria
Filters
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- News Genmab A/S
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
